Commentary: All That Glitters Is Not Zilver: Promises and Disappointments of Endovascular Devices for Superficial Femoral Artery Disease

Abstract

Keywords

angioplasty drug-coated stent drug-eluting stent long lesions patency peripheral artery disease popliteal artery reintervention restenosis superficial femoral artery

Get full access to this article

View all access options for this article.

References

Biondi-Zoccai

. Why interventional cardiologists may be the most suitable specialists for the endovascular management of peripheral artery disease. Minerva Cardioangiol. 2013;61:367–370.

Shanmugasundaram

Ram

Luft

et al . Peripheral arterial disease–what do we need to know? Clin Cardiol. 2011;34:478–482.

TASC Steering Committee, Jaff

White

et al . An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.

Klein

Jaff

Gray

et al . SCAI appropriate use criteria for peripheral arterial interventions: an update. Catheter Cardiovasc Interv. 2017;90:E90–E110.

Biondi-Zoccai

Sangiorgi

D’Ascenzo

et al . Drug-eluting balloons for peripheral artery disease: a meta-analysis of 7 randomized clinical trials and 643 patients. Int J Cardiol. 2013;168:570–571.

Laird

Schneider

Tepe

et al ; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.

Rosenfield

Jaff

White

et al ; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.

Tepe

Schnorr

Albrecht

et al . Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.

Micari

Vadalà

Castriota

et al . 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2016;9:950–956.

10.

Cejna

Thurnher

Illiasch

et al . PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23–31.

11.

Gray

Sullivan

Childs

et al . High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Invasive Cardiol. 2004;16 (suppl A):3A–9A.

12.

Marmagkiolis

Hakeem

Choksi

et al . 12-Month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv. 2014;84:555–564.

13.

Duda

Bosiers

Lammer

et al . Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.

14.

Lammer

Bosiers

Zeller

et al . First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.

15.

Dake

Ansel

Jaff

et al ; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.

16.

Dake

Ansel

Jaff

et al . Zilver PTX Investiga-tors. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.

17.

Siablis

Kitrou

Spiliopoulos

et al . Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048–1056.

18.

Lammer

Zeller

Hausegger

et al . Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38:25–32.

19.

Geraghty

Mewissen

Jaff

et al ; VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386–95.e4.

20.

Lammer

Bosiers

Deloose

et al . Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;9:1178–1187.

21.

Giordano

Ferraro

Corcione

et al . Endovascular therapy for infrainguinal artery disease with coronary devices: a retrospective observational study comparing drug-eluting stents versus bioresorbable vascular scaffolds. Angiology. 2017;68:59–66.

22.

Phillips

Falls

Kolluri

et al . Full drug-eluting stent jacket: 2-year results of a single-center experience with Zilver PTX stenting for long lesions in the femoropopliteal arteries. J Endovasc Ther. 2018;25:295–301.